[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368228-105":59,"doc-detail-368228-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-counting-enables-accurate-and-precise-quantification-of-methylated-ctdna-for-tumor-naive-cancer-therapy-response-monitoring","Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring","","Personalized cancer treatment can extend survival, yet real-time therapy response monitoring remains difficult to achieve with accuracy and operational efficiency. To address limitations of imaging and ctDNA VAF-based assays, a tumor-naive liquid biopsy assay was developed using Quantitative Counting Template (QCT) technology to quantify methylated ctDNA (Northstar Response™). The assay targets \u003C10% coefficient of variation at 1% tumor fraction, resolves 0.25% absolute methylation shifts, and performs across 12 solid tumor types. In a small patient cohort, methylation changes correlated with clinical outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-counting-enables-accurate-and-precise-quantification-of-methylated-ctdna-for-tumor-naive-cancer-therapy-response-monitoring/368228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-counting-enables-accurate-and-precise-quantification-of-methylated-ctdna-for-tumor-naive-cancer-therapy-response-monitoring/368228.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is therapy response monitoring challenging in cancer treatment?","Question",{"text":112,"@type":113},"Accurate and precise monitoring is difficult because imaging can be limited by heterogeneity, pseudoprogression, scarring, low-contrast tissues, and measurement subjectivity, and scans are often infrequent. Quantitative assays based on VAF also face technical constraints that affect precision and usability.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the tumor-naive assay quantify methylated ctDNA?",{"text":117,"@type":113},"The assay uses Quantitative Counting Template (QCT) technology to quantify methylated ctDNA (Northstar Response™) from liquid biopsy samples, aiming to improve accuracy and precision compared with VAF-based targeted approaches.",{"name":119,"@type":110,"acceptedAnswer":120},"What precision and detection performance does the assay achieve?",{"text":121,"@type":113},"It achieves \u003C10% coefficient of variation at 1% tumor fraction, distinguishes 0.25% absolute changes in contrived tumor fraction (AUC > 0.94), and performs well across 12 solid tumor types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368228,1790269803,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMolecular counting enables accurate and precise quantification of methylated ctDNA for tumornaive cancer therapy response monitoring  \nPatrick Peiyong Ye1􀀍, Robb Viens1, Katherine E Shelburne1, Sydne Scot Langpap1,  \nXavier S Bower1, Jonathan Jiahui Shi1, Wen Zhou1, Jan Christian Wignall1, Joyce Jiawei Zhu1, Brian D. Woodward2, Hatim Husain2, David S. Tsao1 & OguzhanAtay1  \nPersonalized cancer treatment can significantly extend survival and improve quality of life for many patients, but accurate and real-time therapy response monitoring remains challenging. To overcome logistical and technical challenges associated with therapy response monitoring via imaging scans or assays that track the variant allele fraction (VAF) of somatic mutations in circulating tumor DNA (ctDNA), we developed a tumor-naive liquid biopsy assay that leverages Quantitative Counting Template (QCT) technology to accurately and precisely quantify methylated ctDNA (Northstar Response™). The assay achieves \u003C 10% coefficient of variation at 1% tumor fraction, which is 2 × lower than tumor-naive, targeted-panel approaches using VAF. The assay accurately distinguishes 0.25% absolute changes in contrived tumor fraction (AUC > 0.94) and performs well in 12 solid tumor types. Finally, in a small cohort of patients with lung, colorectal, or pancreatic cancer, the assay detected changes in ctDNA methylation that correlate with clinical outcomes. With its precise quantification of ctDNA methylation, Northstar Response is a novel tool for therapy response monitoring with the potential to inform clinical decision making for cancer treatment.  \nWhile novel cancer treatments continue to be developed at an unprecedented pace, assessing whether a cancer treatment is effective for a particular patient remains cumbersome and relatively qualitative. Imaging is the current standard for measuring the state of a patient’s cancer; however, therapy response monitoring using imaging faces limitations in accuracy and precision. Specifically, a patient’s response to therapy may not be accurately reflected on imaging due to tumoral heterogeneity1, pseudoprogression in patients receiving immunotherapy2, scar tissue surrounding the tumor, or low contrast in certain tissues like bone and the peritoneum3–5. These measurements may also be imprecise due to the subjectivity involved with measuring radiographic images1. In addition, the relative infrequency of imaging, with scans often several months apart, lengthens the lead time for assessing response to treatment and identifying when a patient is progressing on a particular therapy. Increasing the frequency of imaging can be infeasible due to access, logistics of traveling to imaging centers, and cost. Protein biomarkers have some but limited value for monitoring, with varying utility across cancer types6. Thus, there is a need to more accurately, precisely, and frequently assess the extent to which a patient’s cancer is responding to treatment to inform clinical decision making.  \nNon-invasive liquid biopsies that assay cell-free DNA (cfDNA) have been used to quantify the levels of circulating tumor DNA (ctDNA) from a blood sample7. Several clinical studies have found changes in ctDNA levels to be predictive of progression8–15, indicating that ctDNA contains accurate and quantifiable information for longitudinally tracking tumor progression. These studies use commercially available liquid biopsies that quantify the abundance of ctDNA via measurements ofthe variant allele fraction (VAF) of somatic mutations, using either a tumor-naive, targeted-panel approach or a tumor-informed approach. Tumor-naive, targetedpanel assays face technical limitations for precise therapy response monitoring. First, these assays may not detect somatic mutations in a significant fraction of advanced cancer patients, around 10% to 20% averaged across cancer types15–18, rendering the ","cbCailxP3fZ9BrQP","https://ap.wps.com/l/cbCailxP3fZ9BrQP","pdf",2130134,16,"English","# Therapy response monitoring challenges\n## Limitations of imaging\n## Need for frequent, precise assessment\n# Liquid biopsy and ctDNA quantification approaches\n## Tumor-naive targeted-panel methods and VAF constraints\n## Tumor-informed approaches and operational drawbacks\n# Developed tumor-naive methylated ctDNA assay\n## Quantitative Counting Template (QCT)\n## Precision and sensitivity performance","[{\"question\":\"Why is therapy response monitoring challenging in cancer treatment?\",\"answer\":\"Accurate and precise monitoring is difficult because imaging can be limited by heterogeneity, pseudoprogression, scarring, low-contrast tissues, and measurement subjectivity, and scans are often infrequent. Quantitative assays based on VAF also face technical constraints that affect precision and usability.\"},{\"question\":\"How does the tumor-naive assay quantify methylated ctDNA?\",\"answer\":\"The assay uses Quantitative Counting Template (QCT) technology to quantify methylated ctDNA (Northstar Response™) from liquid biopsy samples, aiming to improve accuracy and precision compared with VAF-based targeted approaches.\"},{\"question\":\"What precision and detection performance does the assay achieve?\",\"answer\":\"It achieves \\u003c10% coefficient of variation at 1% tumor fraction, distinguishes 0.25% absolute changes in contrived tumor fraction (AUC \\u003e 0.94), and performs well across 12 solid tumor types.\"}]","Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring | PDF",1790175773,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e93c299222fbc860d3b6680d589dac3.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d4b50021f42aa447bd55ff2af207614.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd250dca1424a475371eb9a16ed517a7.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74312c038917b31dad1c5099c26cd133.webp",980,1287]